Cargando…

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

ABBV-383, a B-cell maturation antigen × CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human phase I study (ClinicalTrials.gov identifier: NCT03933735) in patients with relapsed/refractory multiple myeloma (RRMM). Herein, we report safety and effic...

Descripción completa

Detalles Bibliográficos
Autores principales:	D'Souza, Anita, Shah, Nina, Rodriguez, Cesar, Voorhees, Peter M., Weisel, Katja, Bueno, Orlando F., Pothacamury, Rajvineeth K., Freise, Kevin J., Yue, Susan, Ross, Jeremy A., Polepally, Akshanth R., Talati, Chetasi, Lee, Shane, Jin, Ziyi, Buelow, Ben, Vij, Ravi, Kumar, Shaji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2022
Materias:	RAPID COMMUNICATIONS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622641/ https://www.ncbi.nlm.nih.gov/pubmed/36029527 http://dx.doi.org/10.1200/JCO.22.01504

Ejemplares similares

P862: A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Weisel, Katja, et al.
Publicado: (2023)

PB2088: ABBV-383 IN COMBINATION WITH ANTI-CANCER REGIMENS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DOSE ESCALATION AND EXPANSION
por: Valdes, Cesar Rodriguez, et al.
Publicado: (2023)

Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma
por: Foureau, David M., et al.
Publicado: (2020)

CFTR Rescue in Intestinal Organoids with GLPG/ABBV-2737, ABBV/GLPG-2222 and ABBV/GLPG-2451 Triple Therapy
por: de Poel, Eyleen, et al.
Publicado: (2021)

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
por: Luke, Jason J, et al.
Publicado: (2021)

Enhancing the antitumor potency of T cells redirected by bispecific antibodies
por: Chang, Chien-Hsing, et al.
Publicado: (2017)

Influence of the bispecific antibody IgG subclass on T cell redirection
por: Kapelski, Stephanie, et al.
Publicado: (2019)

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2020)

Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell–Redirected Bispecific Antibodies
por: Lussana, Federico, et al.
Publicado: (2021)

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors
por: Sun, Zhichen, et al.
Publicado: (2022)

Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody
por: Choi, Bryan D, et al.
Publicado: (2013)

Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells
por: Huckaby, Justin T, et al.
Publicado: (2021)

Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma
por: Hosny, Mashhour, et al.
Publicado: (2021)

Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma
por: Märkl, Florian, et al.
Publicado: (2023)

T‐cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions
por: O'Neill, Chloe, et al.
Publicado: (2023)

Engineering Immune Cells for in vivo Secretion of Tumor-Specific T Cell-Redirecting Bispecific Antibodies
por: Blanco, Belén, et al.
Publicado: (2020)

Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy
por: Lin, Tsung-Yi, et al.
Publicado: (2021)

Bispecific Antibody Format and the Organization of Immunological Synapses in T Cell-Redirecting Strategies for Cancer Immunotherapy
por: Carrasco-Padilla, Carlos, et al.
Publicado: (2022)

Nuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectives
por: Talati, Chetasi, et al.
Publicado: (2018)

MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody
por: Li, Hongjian, et al.
Publicado: (2020)

Efficient and Highly Specific Gene Transfer Using Mutated Lentiviral Vectors Redirected with Bispecific Antibodies
por: Parker, Christina L., et al.
Publicado: (2020)

Bispecific Antibody Inhalation Therapy for Redirecting Stem Cells from the Lungs to Repair Heart Injury
por: Liu, Mengrui, et al.
Publicado: (2020)

Conduit CAR: Redirecting CAR T-Cell Specificity with A Universal and Adaptable Bispecific Antibody Platform
por: Borrok, M. Jack, et al.
Publicado: (2022)

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Exposure–Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients
por: Khatri, Amit, et al.
Publicado: (2019)

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study
por: Paz-Ares, Luis, et al.
Publicado: (2023)

Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells
por: Strohl, William R., et al.
Publicado: (2019)

In vivo kinetics of Wolbachia depletion by ABBV-4083 in L. sigmodontis adult worms and microfilariae
por: Hübner, Marc P., et al.
Publicado: (2019)

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
por: Hutchings, Martin, et al.
Publicado: (2021)

Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning
por: Haber, Lauric, et al.
Publicado: (2021)

Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with multiple myeloma: a systematic review and meta-analysis
por: Noori, Maryam, et al.
Publicado: (2023)

Transcriptome Analysis of Duck and Chicken Brains Infected with Aquatic Bird Bornavirus-1 (ABBV-1)
por: Pham, Phuc H., et al.
Publicado: (2022)

Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis‐Associated Pain: An Application of Markov Model
por: Winzenborg, Insa, et al.
Publicado: (2020)

Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy
por: Huang, Cheng, et al.
Publicado: (2020)

A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells
por: Lund, Maria E., et al.
Publicado: (2020)

Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours
por: Sano, Yuji, et al.
Publicado: (2022)

Proton-proton scattering at 383 Mev
por: Holt, J R, et al.
Publicado: (1956)

Targeting Human-Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3/Anti-Glycoprotein B Bispecific Antibody
por: Meng, Weixu, et al.
Publicado: (2017)

GLP toxicology study of a fully-human T cell redirecting CD3:EGFRvIII binding immunotherapeutic bispecific antibody
por: Gedeon, Patrick C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5dtjtnslq18n98mt7s8tdek2gs